Skip to main content

Table 4 Clinical and biochemical parameters at baseline and at week 12 of liraglutide treatment

From: Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study

Items

Mean value ± SD

n

Change (SE)

p value

Baseline

Week 12

Weight (kg)

73.9 ± 17.0

72.5 ± 16.7

204

−1.4 (0.3)

<0.001

BMI (kg/m2)

27.9 ± 5.3

27.3 ± 5.2

203

−0.5 (0.1)

<0.001

Systolic blood pressure (mmHg)

131.1 ± 15.4

129.4 ± 16.0

203

−1.8 (1.2)

0.134

Diastolic blood pressure (mmHg)

76.0 ± 11.6

76.4 ± 12.2

203

0.4 (0.8)

0.652

HbA1c (NGSP, %)

8.7 ± 1.5

7.5 ± 1.3

203

−1.2 (0.1)

<0.001

Random blood glucose level (mg/dL)

199 ± 80

170 ± 66

198

−29.0 (5.8)

<0.001

RBCs (×104/μL)

459 ± 54

458 ± 50

135

−1.1 (2.5)

0.661

WBCs (/mm3)

6887 ± 1879

6913 ± 1876

135

26.4 (140.4)

0.851

Hemoglobin (g/dL)

13.9 ± 1.6

13.9 ± 1.5

135

0.0 (0.1)

0.886

Hematocrit (%)

41.6 ± 4.2

41.8 ± 4.2

135

0.2 (0.2)

0.225

Blood platelets (×104/μL)

22.5 ± 6.2

23.1 ± 5.7

134

0.6 (0.4)

0.088

AST (IU/L)

28.1 ± 20.6

26.6 ± 19.3

162

−1.5 (1.1)

0.176

ALT (IU/L)

36.1 ± 33.1

33.5 ± 29.0

160

−2.7 (1.6)

0.090

γGTP (IU/L)

50.0 ± 52.7

50.2 ± 64.8

153

0.2 (2.9)

0.943

Serum creatinine (mg/dL)

0.9 ± 1.0

0.9 ± 0.9

162

0.0 (0.0)

0.215

Uric acid (mg/dL)

5.6 ± 1.5

5.4 ± 1.4

151

−0.2 (0.1)

0.025

TC (mg/dL)

189.1 ± 36.5

180.8 ± 32.2

117

−8.4 (2.8)

0.003

HDL-C (mg/dL)

50.9 ± 12.9

49.7 ± 12.5

155

−1.2 (0.6)

0.041

TG (mg/dL)

177.9 ± 130.3

172.3 ± 100.8

166

−5.6 (7.4)

0.451

  1. BL baseline, w12 week 12, RBCs red blood cells, WBCs white blood cells, BMI body mass index HbA1c hemoglobin A1c, NGSP National Glycohemoglobin Standardization Program, AST aspartate aminotransferase, ALT alanine aminotransferase, γGTP γ-glutamyl transpeptidase, TC total cholesterol, HDL-C high density lipoprotein cholesterol, TG triglyceride
  2. p values are the results of paired t test